Proto Script Pharmaceutical (Proto Script Pharmaceutical) EV-to-EBITDA : 0.00 (As of May. 11, 2024)

Proto Script Pharmaceutical EV-to-EBITDA Chart

Proto Script Pharmaceutical Quarterly Data
	Nov12	Feb13	May13	Aug13	Nov13	Feb14	May14	Aug14	Nov14	Feb15	May15	Aug15	Nov15	Feb16	May16	Sep16	Dec16	Mar17	Jun17	Sep17
EV-to-EBITDA	Get a 7-Day Free Trial															-995.81	-659.66	-5.52	-3.24	-2.77

Competitive Comparison of Proto Script Pharmaceutical's EV-to-EBITDA

For the Specialty Business Services subindustry, Proto Script Pharmaceutical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Proto Script Pharmaceutical's EV-to-EBITDA Distribution in the Business Services Industry

For the Business Services industry and Industrials sector, Proto Script Pharmaceutical's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Proto Script Pharmaceutical's EV-to-EBITDA falls into.

Proto Script Pharmaceutical EV-to-EBITDA Calculation

Proto Script Pharmaceutical's EV-to-EBITDA for today is calculated as:

Proto Script Pharmaceutical's current Enterprise Value is $0.00 Mil.
Proto Script Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Proto Script Pharmaceutical  (OTCPK:PSCR) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Proto Script Pharmaceutical's PE Ratio for today is calculated as:

Proto Script Pharmaceutical's share price for today is $0.0002.
Proto Script Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.044.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Proto Script Pharmaceutical EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Proto Script Pharmaceutical's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Proto Script Pharmaceutical (Proto Script Pharmaceutical) Business Description